Blood Pressure-Lowering Targets in Patients With Diabetes Mellitus

被引:1
|
作者
Leung, Alexander A. [1 ,2 ]
Padwal, Raj S. [3 ]
机构
[1] Univ Calgary, Dept Med, Calgary, AB, Canada
[2] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
[3] Univ Alberta, Dept Med, Edmonton, AB, Canada
关键词
RECEIVE INTENSIVE TREATMENT; MM HG TARGET; RISK-FACTORS; INTERNATIONAL-SOCIETY; HYPERTENSION; MANAGEMENT; GUIDELINES; TRIAL; INTERVENTION; MORTALITY;
D O I
10.1016/j.cjca.2017.10.024
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes is a highly prevalent medical condition that commonly coexists with hypertension. The presence of diabetes and hypertension significantly increases the risk of adverse cardiovascular events. Although compelling evidence exists from randomized controlled trials demonstrating that blood pressure (BP) reduction effectively prevents cardiovascular complications, optimal BP targets remain uncertain and continue to be the subject of ongoing controversy. Until recently, most major clinical practice guidelines recommended a BP target of < 130/80 mm Hg, but some expert panels have raised their recommended treatment targets in recent years. The primary benefit of more intensive BP reduction appears to be prevention of stroke, but this is balanced against an increase in treatment burden, side effects, and cost. The purpose of this review is to summarize the global body of evidence evaluating BP targets as well as to compare the recommendations from different clinical practice guidelines, which inform the treatment of patients with hypertension and diabetes.
引用
下载
收藏
页码:644 / 652
页数:9
相关论文
共 50 条
  • [1] Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus The YESTONO Study
    Schmidt, A. C.
    Graf, Ch
    Brixius, K.
    Scholze, J.
    CARDIOVASCULAR THERAPY AND PREVENTION, 2010, 9 (07): : 33 - 40
  • [2] Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: The Yestono study
    Schmidt, Andre C.
    Graf, Christine
    Brixius, Klara
    Scholze, Juergen
    CLINICAL DRUG INVESTIGATION, 2007, 27 (12) : 841 - 849
  • [3] BLOOD PRESSURE-LOWERING, ANTIHYPERTENSIVE TREATMENT AND INCIDENT DIABETES
    Nazarzadeh, Milad
    Bidel, Zeinab
    Canoy, Dexter
    Copland, Emma
    Wamil, Malgorzata
    Byrne, Karl Smith
    Sundstrom, Johan
    Teo, Koon
    Davis, Barry R.
    Chalmers, John
    Pepine, Carl J.
    Dehghan, Abbas
    Bennet, Derrick A.
    Smith, George Davey
    Rahimi, Kazem
    JOURNAL OF HYPERTENSION, 2021, 39 : E8 - E9
  • [4] New Blood Pressure-Lowering Targets-Finding Clarity
    Yancy, Clyde W.
    Bonow, Robert O.
    JAMA CARDIOLOGY, 2017, 2 (07) : 719 - 720
  • [5] Blood pressure-lowering effect of melatonin in type 1 diabetes
    Cavallo, A
    Daniels, SR
    Dolan, LM
    Bean, JA
    Khoury, JC
    JOURNAL OF PINEAL RESEARCH, 2004, 36 (04) : 262 - 266
  • [6] Blood Pressure Lowering and Outcomes in type 2 Diabetes: Implications of the Blood Pressure-Lowering Arm of the Advance Trial
    MacIsaac, Richard J.
    Barit, David
    Jerums, George
    CURRENT HYPERTENSION REVIEWS, 2009, 5 (03) : 168 - 180
  • [8] Blood Pressure-Lowering Effects of Incretin-Based Diabetes Therapies
    Lovshin, Julie A.
    Zinman, Bernard
    CANADIAN JOURNAL OF DIABETES, 2014, 38 (05) : 364 - 371
  • [9] Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes
    Hirakawa, Yoichiro
    Arima, Hisatomi
    Webster, Ruth
    Zoungas, Sophia
    Li, Qiang
    Harrap, Stephen
    Liu Lisheng
    Hamet, Pavel
    Mancia, Giuseppe
    Poulter, Neil
    Neal, Bruce
    Williams, Bryan
    Rogers, Anthony
    Woodward, Mark
    Chalmers, John
    JOURNAL OF HYPERTENSION, 2016, 34 (04) : 781 - 787
  • [10] Blood Pressure-Lowering Treatment Should Be Offered to All Patients Regardless of Blood Pressure
    McManus, Richard J.
    Mant, Jonathan
    JOURNAL OF CLINICAL HYPERTENSION, 2009, 11 (12): : 698 - 701